Eli Lilly’s Obesity-Drug Beat Lifts Stocks as the Market Awaits Friday’s Jobs Report

Georgi Kuzmanov Senior Equity Analyst & Founder Columbia MSFE · 13+ years equity research

The week’s second great secular theme just delivered. A day after AMD broadened the AI trade, Eli Lilly reported before Thursday’s open and posted a blowout quarter for its GLP-1 franchise — obesity- and diabetes-drug sales well ahead of expectations, a raised full-year outlook, and an encouraging update on its oral formulation pipeline. The stock jumped roughly 5% premarket and dragged the entire weight-loss complex higher with it, from Novo Nordisk to the ecosystem of suppliers around the category. Within one week, the market’s two biggest multi-year growth stories — AI hardware and GLP-1 drugs — have both been reaffirmed.

That is a powerful backdrop, and it leaves the S&P 500 sitting at a record after Wednesday’s AMD-fueled push toward 8,000. Yet the tone this morning is one of patience, not celebration. Futures are little changed, because the market knows that everything it has built this week now runs into a single event tomorrow: the July employment report. No earnings beat, however impressive, changes the fact that Friday’s payrolls will set the September rate-cut odds and, with them, the near-term direction of the tape.

Today is the last full session before that test. Weekly jobless claims and second-quarter unit labor costs arrive at 8:30 a.m. as the final labor data points ahead of payrolls, Airbnb headlines the after-hours slate, and the market settles into the holding pattern that typically precedes a make-or-break number. The record is intact; the verdict is 24 hours away.

Pre-Market Snapshot

Overnight Developments

Eli Lilly’s GLP-1 blowout lifts the obesity complex

Eli Lilly’s report was the healthcare event of the week, and it landed emphatically. Sales of its GLP-1 obesity and diabetes drugs came in well above consensus, the company raised its full-year revenue and earnings guidance, and management struck a confident tone on the progress of its oral obesity treatment — the next frontier for a category so far dominated by injectables. The stock rose about 5% premarket, and the read-through lifted Novo Nordisk and the broader weight-loss ecosystem. The print reaffirms that GLP-1 remains one of the most powerful secular growth stories in the market, and it gave a lagging, defensive healthcare sector its strongest single catalyst in months.

The record run meets the pre-payrolls pause

Wednesday closed at a record as AMD’s data-center blowout broadened the AI trade and a benign ISM services report kept the disinflation narrative intact, carrying the S&P 500 to the doorstep of 8,000. This morning, that momentum meets the natural caution that precedes a jobs report. The market has priced a great deal of good news — a September cut, resilient growth, broadening AI leadership — and with the VIX still near 13.7, there is little cushion in the tape. Expect a quieter, more two-sided session as traders trim exposure into Friday rather than chase the record higher.

Jobless claims and the final labor read

The data slate is a warm-up act. Initial jobless claims at 8:30 a.m. are expected near 240,000, and the market will watch for any upward drift that would corroborate the gradual labor-market cooling the Fed has described. Second-quarter unit labor costs, a gauge of wage-driven inflation pressure, accompany the claims figure. Neither is likely to move the tape much on its own, but a sharp jump in claims would set a cautious tone into tomorrow’s payrolls — the release that actually decides the week.

Global Markets

Asian markets were mixed as the AMD-driven chip euphoria cooled and caution built ahead of the US jobs data. Japan’s Nikkei 225 was little changed near 76,400, Taiwan’s Taiex eased 0.2% after its strong run, South Korea’s Kospi firmed 0.3%, China’s Shanghai Composite added 0.2% to about 4,300, and Hong Kong’s Hang Seng rose 0.4% to around 25,860. The tone was one of consolidation after a strong week for the region’s technology names.

Europe opened firmer, led by healthcare on the Eli Lilly read-through. Denmark’s market outperformed as Novo Nordisk rallied in sympathy, Germany’s DAX rose about 0.3% to near 26,500, France’s CAC 40 added 0.2% to around 8,885, Britain’s FTSE 100 firmed 0.2% to about 10,995, and the Euro Stoxx 50 gained modestly. The obesity-drug complex was the clear regional winner, echoing the strength in US pharma.

Macro and Rates

The bond market held steady in the pre-payrolls calm. The 10-year Treasury yield sat near 4.35% and the 2-year near 3.99%, keeping the 2s/10s spread at a positive 36 basis points as the front end continues to discount a September cut, priced at roughly a two-thirds probability. Today’s claims and unit-labor-cost data are second-order relative to tomorrow’s payrolls; the market is essentially in a holding pattern, unwilling to take a strong directional view on rates until it sees the July jobs number and its implication for the September decision.

Across other assets, the dollar was soft near 98.4 on the ICE index, gold firmed to $4,162 as some pre-event hedging crept in, and crude eased again toward $68.80 as the OPEC+ supply increase continued to pressure the barrel. Bitcoin held near $75,800. The cross-asset backdrop remains supportive, but the modest bid in gold and the calm in rates both reflect the same thing: a market marking time, its conviction reserved for Friday morning.

Corporate News

Earnings & Analyst Actions

• Eli Lilly (LLY): Rose about 5% premarket on a GLP-1 sales blowout, raised guidance, and an encouraging oral-drug pipeline update; analysts lifted targets.
• Novo Nordisk (NVO): Firmed in sympathy as Lilly’s strength reaffirmed the obesity-drug category’s momentum.
• AMD (AMD): Held its post-earnings gains as analysts continued to raise targets on the data-center acceleration.
• Airbnb (ABNB): Reports after the close; nights booked and the travel-demand outlook are the watch metrics on the consumer.
• ConocoPhillips (COP): Traded lower with the energy sector as crude stayed soft below $69.

Premarket Movers

Economic Calendar

The AlphaEdge Prediction

The most likely session is a quiet, record-holding Thursday, with Eli Lilly and the healthcare complex providing a bid and the broad index drifting in a narrow range as the market de-risks modestly into Friday’s payrolls. Expect the obesity-drug names to lead, the AI winners to hold their gains, and volume to thin through the afternoon as traders square up ahead of the jobs data.

Base case: The S&P 500 trades a 7,940–7,985 range and closes little changed near its record, with Lilly’s strength offset by pre-payrolls caution and a benign claims report.

Bull case: The Lilly-led healthcare bid combines with residual AMD momentum and a low claims print to push the index to a first test of 8,000.

Bear case: A jump in jobless claims revives labor-market worries, or broad pre-payrolls de-risking pulls the S&P back toward 7,910 as the market trims exposure into the binary.

This has been a rare week in which the market’s two biggest secular growth stories — AI hardware through AMD and GLP-1 drugs through Eli Lilly — both delivered decisive validation, and that double confirmation is a genuine, Fed-independent support for the record the index now holds; but none of it changes the single fact that governs the next 24 hours, which is that Friday’s payrolls will set the September-cut odds and the near-term direction of the tape, so treat today as the deep breath before the number, lean on the quality that just proved itself, and resist the temptation to carry fresh conviction into a jobs print the market has priced to perfection.

Georgi Kuzmanov

Senior Equity Analyst & Founder at AlphaEdge. Columbia University MSFE (2011–2013). Covering equities, macro, and geopolitics for serious investors.